GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » Cash Conversion Cycle

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Cash Conversion Cycle : 326.70 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Tianjin Chase Sun Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 173.25.
Tianjin Chase Sun Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 was 245.51.
Tianjin Chase Sun Pharmaceutical Co's Days Payable for the three months ended in Mar. 2024 was 92.06.
Therefore, Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 326.70.


Tianjin Chase Sun Pharmaceutical Co Cash Conversion Cycle Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co Cash Conversion Cycle Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.18 196.72 220.18 320.47 349.82

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 359.61 343.66 365.81 416.48 326.70

Competitive Comparison of Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle falls into.



Tianjin Chase Sun Pharmaceutical Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=182.09+271.77-104.04
=349.82

Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=173.25+245.51-92.06
=326.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Chase Sun Pharmaceutical Co  (SZSE:300026) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Tianjin Chase Sun Pharmaceutical Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Business Description

Traded in Other Exchanges
N/A
Address
No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700
Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.
Executives
Yao Xiao Qing Director
Chen Rui Qiang Executives
Li Chun Xu Executives
Lan Wu Jun Directors, Directors, and Executives
Zheng Dan Directors, executives
Zhang Kun Executives
Gao Guo Wei Executives
Shang Xiao Mei Securities Affairs Representative
Sun Zhang Hai Director
Wu Guang Ning Supervisors
Wang Long Executives
Liu Qiang Supervisors
Ceng Guo Zhuang Director
Su Bing Jun Directors, executives
Nie Wei Supervisors

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Headlines

No Headlines